ViiV's Cabenuva is administered every two months and was offered to HIV patients who achieved viral suppression from daily treatments.

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial of the highly selective ASI, baxdrostat.

The timing of the exposure during pregnancy made a big difference in the level of risk associated with developing an allergic condition.

MSD unveiled the launch of the Phase III trials of MK-8527 at the International AIDS Society (IAS) 2025 conference.

Takeda’s oral narcolepsy drug, oveporexton, has met the primary and secondary endpoints in two Phase III trials. The FirstLight (NCT06470828) and RadiantLight (NCT06505031) trials both met all their ...

Crinetics Pharmaceuticals has revealed new data from its clinical development programme for Palsonify, an oral treatment for acromegaly.

UK & Ireland, experts provided insights on market trends within the clinical trial industry and advice on engagement strategies.

The US FDA has approved Purespring Therapeutics’ IND application for PS-002, allowing the company to begin a Phase I/II trial.

A panel at CTO East Coast discussed the regulatory changes impacting oncology trials and how these can be managed.

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the psychedelic in ...

UroGen Pharma has completed the enrolment of subjects in its Phase III UTOPIA trial, which is evaluating UGN-103 for intravesical solution.

Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with nmHSPC, but only as a combination therapy.